SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Lowy F.D. (1998) Staphylococcus aureus infections. N Engl J Med 339: 52032.
  • 2
    Chambers H.F., DeLeo F.R. (2009) Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat Rev Microbiol 7: 62941.
  • 3
    Proctor R.A. (2012) Challenges for a Universal Staphylococcus aureus Vaccine. Clin Infect Dis 54: 117986.
  • 4
    Leitner G., Krifucks O., Kiran M.D., Balaban N. (2011) Vaccine development for the prevention of staphylococcal mastitis in dairy cows. Vet Immunol Immunopathol 142: 2535.
  • 5
    Balaban N. (1998) Autoinducer of Virulence As a Target for Vaccine and Therapy Against Staphylococcus aureus. Science 280: 43840.
  • 6
    Balaban N., Goldkorn T., Gov Y., Hirshberg M., Koyfman N., Matthews H.R., Nhan R.T., Singh B., Uziel O. (2001) Regulation of Staphylococcus aureus pathogenesis via target of RNAIII-activating protein (TRAP). J Biol Chem 276: 265867.
  • 7
    Harro C.D., Betts R.F., Orenstein W., Kwak E.J., Greenberg H.E., Onorato M.T., Hartzel J., Lipka J., DiNubile M.J., Kartsonis N.A. (2010) Safety and immunogenicity of a novel Staphylococcus aureus vaccine: results from the first study of the vaccine dose range in humans. Clin Vaccine Immunol 17: 186874.
  • 8
    Harro C.D., Betts R.F., Hartzel J.S., Onorato M.T., Lipka J., Smugar S.S., Kartsonis N.A. (2012) The immunogenicity and safety of different formulations of a novel Staphylococcus aureus vaccine (V710): results of two Phase I studies. Vaccine 30: 172936.
  • 9
    Gov Y., Borovok I., Korem M., Singh V.K., Jayaswal R.K., Wilkinson B.J., Rich S.M., Balaban N. (2004) Quorum sensing in Staphylococci is regulated via phosphorylation of three conserved histidine residues. J Biol Chem 279: 1466572.
  • 10
    Korem M., Gov Y., Kiran M.D., Balaban N. (2005) Transcriptional profiling of target of RNAIII-activating protein, a master regulator of staphylococcal virulence. Infect Immun 73: 62208.
  • 11
    Shaw L.N., Jonsson I.M., Singh V.K., Tarkowski A., Stewart G.C. (2007) Inactivation of traP has no effect on the Agr quorum-sensing system or virulence of Staphylococcus aureus. Infect Immun 75: 451927.
  • 12
    Adhikari R.P., Arvidson S., Novick R.P. (2007) A nonsense mutation in agrA accounts for the defect in agr expression and the avirulence of Staphylococcus aureus8325-4 traP::kan. Infect Immun 75: 453440.
  • 13
    Tsang L.H., Daily S.T., Weiss E.C., Smeltzer M.S. (2007) Mutation of traP in Staphylococcus aureus has no impact on expression of agr or biofilm formation. Infect Immun 75: 452833.
  • 14
    Yang G. (2005) A novel peptide screened by phage display can mimic TRAP antigen epitope against Staphylococcus aureus infections. J Biol Chem 280: 274315.
  • 15
    Mazmanian S.K., Skaar E.P., Gaspar A.H., Humayun M., Gornicki P., Jelenska J., Joachmiak A., Missiakas D.M., Schneewind O. (2003) Passage of heme–iron across the envelope of Staphylococcus aureus. Science 299: 9069.
  • 16
    Kuklin N.A., Clark D.J., Secore S., Cook J., Cope L.D., McNeely T., Noble L., Brown M.J., Zorman J.K., Wang X.M., Pancari G., Fan H., Isett K., Burgess B., Bryan J., Brownlow M., George H., Meinz M., Liddell M.E., Kelly R., Schultz L., Montgomery D., Onishi J., Losada M., Martin M., Ebert T., Tan C.Y., Schofield T.L., Nagy E., Meineke A., Joyce J.G., Kurtz M.B., Caulfield M.J., Jansen K.U., McClements W., Anderson A.S. (2006) A novel Staphylococcus aureus vaccine: iron surface determinant B induces rapid antibody responses in rhesus macaques and specific increased survival in a murine S. aureus sepsis model. Infect Immun 74: 221523.
  • 17
    Kim H.K., DeDent A., Cheng A.G., McAdow M., Bagnoli F., Missiakas D.M., Schneewind O. (2010) IsdA and IsdB antibodies protect mice against Staphylococcus aureus abscess formation and lethal challenge. Vaccine 28: 638292.
  • 18
    Moustafa M., Aronoff G.R., Chandran C., Hartzel J.S., Smugar S.S., Galphin C.M., Mailloux L.U., Brown E., DiNubile M.J., Kartsonis N.A., Guris D. (2012) Phase IIa study of the immunogenicity and safety of the novel Staphylococcus aureus vaccine V710 in adults with end-stage renal disease receiving hemodialysis. Clin Vaccine Immunol 19: 150916.
  • 19
    Chong K.T. (1987) Prophylactic administration of interleukin-2 protects mice from lethal challenge with gram-negative bacteria. Infect Immun 55: 66873.
  • 20
    Howden B.P., Davies J.K., Johnson P.D., Stinear T.P., Grayson M.L. (2010) Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev 23: 99139.
  • 21
    Locke J.B., Hilgers M., Shaw K.J. (2009) Novel ribosomal mutations in Staphylococcus aureus strains identified through selection with the oxazolidinones linezolid and torezolid (TR-700). Antimicrob Agents Chemother 53: 526574.
  • 22
    Mendes R.E., Deshpande L.M., Castanheira M., DiPersio J., Saubolle M.A., Jones R.N. (2008) First report of cfr-mediated resistance to linezolid in human staphylococcal clinical isolates recovered in the United States. Antimicrob Agents Chemother 52: 22446.
  • 23
    Fowler V.G., Jr., Boucher H.W., Corey G.R., Abrutyn E., Karchmer A.W., Rupp M.E., Levine D.P., Chambers H.F., Tally F.P., Vigliani G.A., Cabell C.H., Link A.S., DeMeyer I., Filler S.G., Zervos M., Cook P., Parsonnet J., Bernstein J.M., Price C.S., Forrest G.N., Fatkenheuer G., Gareca M., Rehm S.J., Brodt H.R., Tice A., Cosgrove S.E. (2006) Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 355: 65365.
  • 24
    Proctor R.A. (2012) Challenges for a universal Staphylococcus aureus vaccine. Clin Infect Dis 54: 117986.
  • 25
    Duthie M.S., Sampaio L.H., Oliveira R.M., Raman V.S., O'Donnell J., Bailor H.R., Ireton G.C., Sousa A.L., Stefani M.M., Reed S.G. (2013) Development and pre-clinical assessment of a 73 kD chimeric fusion protein as a defined sub-unit vaccine for leprosy. Vaccine 31: 8139.
  • 26
    Qiu X., Hong C., Li Y., Bao W., Gao X.M. (2012) Calreticulin as a hydrophilic chimeric molecular adjuvant enhances IgG responses to the spike protein of severe acute respiratory syndrome coronavirus. Microbiol Immunol 56: 55461.
  • 27
    Fischetti V.A., Pancholi V., Schneewind O. (1990) Conservation of a hexapeptide sequence in the anchor region of surface proteins from gram-positive cocci. Mol Microbiol 4: 16035.
  • 28
    Aoki W., Kitahara N., Miura N., Morisaka H., Kuroda K., Ueda M. (2012) Design of a novel antimicrobial peptide activated by virulent proteases. Chem Biol Drug Des 80: 72533.
  • 29
    Sathiyaseelan J., Goenka R., Parent M., Benson R.M., Murphy E.A., Fernandes D.M., Foulkes A.S., Baldwin C.L. (2006) Treatment of Brucella susceptible mice with IL-12 increases primary and secondary immunity. Cell Immunol 243: 19.
  • 30
    Brouillette E., Lacasse P., Shkreta L., Belanger J., Grondin G., Diarra M.S., Fournier S., Talbot B.G. (2002) DNA immunization against the clumping factor A (ClfA) of Staphylococcus aureus. Vaccine 20: 234857.
  • 31
    Shkreta L., Talbot B.G., Diarra M.S., Lacasse P. (2004) Immune responses to a DNA/protein vaccination strategy against Staphylococcus aureus induced mastitis in dairy cows. Vaccine 23: 11426.